Hanmi Science Co Ltd
KRX:008930
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
26 750
56 200
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Hanmi Science Co Ltd
Hanmi Science Co Ltd
Short-Term Debt
Hanmi Science Co Ltd
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hanmi Science Co Ltd
KRX:008930
|
Short-Term Debt
₩202.5B
|
CAGR 3-Years
57%
|
CAGR 5-Years
36%
|
CAGR 10-Years
11%
|
|
|
Yuhan Corp
KRX:000100
|
Short-Term Debt
₩131.7B
|
CAGR 3-Years
27%
|
CAGR 5-Years
47%
|
CAGR 10-Years
18%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Short-Term Debt
₩50B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Short-Term Debt
₩365.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
21%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Short-Term Debt
₩22.5B
|
CAGR 3-Years
115%
|
CAGR 5-Years
51%
|
CAGR 10-Years
20%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Short-Term Debt
₩150.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
Hanmi Science Co Ltd
Glance View
Hanmi Science Co., Ltd. engages in the management of its subsidiaries. The company is headquartered in Hwaseong, Gyeonggi-Do. Through subsidiaries in Japan, Europe and Korea, the Company operates in three segments. The Pharmaceutical Products Wholesale segment mainly engages in the distribution of pharmaceutical products. The Holding Business segment mainly engages in the business of controlling subsidiaries. The Other segment mainly engage in the production and sales of pharmaceuticals, and the supply of quasi-drugs and health functional foods, beverages and functional cosmetics.
See Also
What is Hanmi Science Co Ltd's Short-Term Debt?
Short-Term Debt
202.5B
KRW
Based on the financial report for Sep 30, 2024, Hanmi Science Co Ltd's Short-Term Debt amounts to 202.5B KRW.
What is Hanmi Science Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 10Y
11%
Over the last year, the Short-Term Debt growth was 12%. The average annual Short-Term Debt growth rates for Hanmi Science Co Ltd have been 57% over the past three years , 36% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
